Twist Bioscience Files for $200M Mixed Shelf Offering
TWST has more than doubled off its 52-week low of $23.3 on elevated volume (2.5× avg).
Summary
Twist Bioscience has filed for a mixed shelf offering, establishing an At-The-Market (ATM) program to sell up to $200 million in common stock. This follows the S-3ASR filing earlier today, which initiated the ATM program. The offering provides the company with capital raising flexibility, which is relevant given its reported increased net losses and cash burn in the last 10-Q. While it secures future funding options, it also signals potential dilution for existing shareholders.
At the time of this announcement, TWST was trading at $83.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.5B. The 52-week trading range was $23.30 to $88.46. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Reuters.